Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
暂无分享,去创建一个
N. Agarwal | C. Drake | H. Scher | S. Hansen | C. Logothetis | T. Ciuleanu | M. Maio | A. Bergman | S. Sundar | N. Houédé | F. Franke | L. Sengeløv | K. Fizazi | T. Beer | M. Krainer | W. Gerritsen | A. van den Eertwegh | A. Bossi | M. McHenry | E. Kwon | S. Ng | P. Gagnier | E. Korbenfeld | M. AlfonsJ. | H. Mahammedi | van den Eertwegh | David Liu | R. Santos | M AlfonsJ | van den Eertwegh | M Andries | Bergman | M. Andries | Bergman | Charles G. Drake | Eugene D Kwon | Fabio A. Franke | T. M. Beer | M. McHenry | Eugene D. Kwon